Exela Pharma Sciences
Pharmaceuticals, 1245 Blowing Rock BLVD, Lenoir, North Carolina, 28645, United States, 501-1000 Employees
Phone Number: 82********
Who is EXELA PHARMA SCIENCES
Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic produc...
Read More
-
Headquarters: 1245 Blowing Rock BLVD, Lenoir, North Carolina, 28645, United States
-
Date Founded: 2005
-
Employees: 501-1000
-
Revenue: $100 Million to $250 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 7389
|
NAICS Code: 621111 |
Show More
Does something look wrong? Fix it. | View contact records from EXELA PHARMA SCIENCES
Exela Pharma Sciences Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Exela Pharma Sciences
Answer: Exela Pharma Sciences's headquarters are located at 1245 Blowing Rock BLVD, Lenoir, North Carolina, 28645, United States
Answer: Exela Pharma Sciences's phone number is 82********
Answer: Exela Pharma Sciences's official website is https://exelapharma.com
Answer: Exela Pharma Sciences's revenue is $100 Million to $250 Million
Answer: Exela Pharma Sciences's SIC: 7389
Answer: Exela Pharma Sciences's NAICS: 621111
Answer: Exela Pharma Sciences has 501-1000 employees
Answer: Exela Pharma Sciences is in Pharmaceuticals
Answer: Exela Pharma Sciences contact info: Phone number: 82******** Website: https://exelapharma.com
Answer: Exela Pharma Sciences, a fast-growing specialty pharmaceutical company, focuses on developing, manufacturing and marketing generic and proprietary injectable and sterile ophthalmic products that keep the healthcare provider and patient in mind. Our goal is to deliver high quality, affordable products that make a difference in peoples lives, and also meet the needs of the healthcare providers that treat them. Exela targets the development and manufacturing of generic and proprietary injectable and sterile ophthalmic products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug preparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month